Sai Life Sciences posts stellar Q3, revenue surges 27% YoY; PAT nearly doubles
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
Capital expenditure stood at Rs. 405 crore to date against a planned Rs. 700 crore for FY26
LIVMARLI’s new tablet form offers patients weighing 22 kg or more a convenient, one-tablet-per-dose option, complementing the existing 9.5 mg/ml oral solution
Leading the showcase is FCT iStream, Fujifilm’s latest CT scanner built on a “Less is More” design philosophy
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
Hologic has been at the forefront of cervical cancer screening for decades
Venglustat, a glucosylceramide synthase inhibitor (GCSi), works by reducing the abnormal buildup of sugar-and-fat molecules in cells and organs
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
The study tested whether PF’3944 could maintain efficacy when switching from weekly to monthly injections and remain safe and well-tolerated
Subscribe To Our Newsletter & Stay Updated